ImmunoPrecise Antibodies (NASDAQ:IPA) Issues Quarterly Earnings Results

ImmunoPrecise Antibodies (NASDAQ:IPA) released its earnings results on Friday. The company reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of ($0.06), Zacks reports. ImmunoPrecise Antibodies had a negative return on equity of 73.74% and a negative net margin of 114.50%.

ImmunoPrecise Antibodies Price Performance

Shares of IPA traded down $0.03 during trading hours on Friday, reaching $0.41. The stock had a trading volume of 178,395 shares, compared to its average volume of 7,933,911. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.85 and a current ratio of 1.01. ImmunoPrecise Antibodies has a 12 month low of $0.27 and a 12 month high of $1.59. The stock has a market capitalization of $12.74 million, a PE ratio of -0.53 and a beta of 0.09. The company’s 50-day moving average is $0.44 and its two-hundred day moving average is $0.48.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of ImmunoPrecise Antibodies in a research report on Friday, March 14th.

ImmunoPrecise Antibodies Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.